Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure

Raquel Araujo-Gutierrez1, Sergio H. Ibarra‐Cortez2, Jerry D. Estep3, Arvind Bhimaraj3, Ashrith Guha3, Imad Hussain3, Myung H. Park3, Guillermo Torre‐Amione3, Barry Trachtenberg3
1Department of Heart Failure & Transplant Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, USA
2Department of Structural Heart Disease, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, USA
3Department of Heart Failure & Transplant Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

DeSantis CE, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.

Kero AE, et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer. 2014;134(3):664–73.

Oliveira GH, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS registry (interagency registry for mechanically assisted circulatory support). J Am Coll Cardiol. 2014;63(3):240–8.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

Pein F, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91(1):37–44.

Andersson A, et al. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914–7.

Hooning MJ, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–75.

Oliveira GH, et al. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circ Heart Fail. 2014;7(6):1050–8.

Oliveira GH, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805–10.

Lenneman AJ, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609–12.

Hall PS, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–8.

Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

Website I. INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report. Implant dates: June 23, 2006-March 31, 2011. National Heart Lung and Blood Institute. Contract Award HHSN268201100025C. http://www.uab.edu/intermacs .